Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

PHASE1RecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
DRUG

ISB 2001

Participants will receive escalating doses of ISB 2001

DRUG

ISB 2001

Participants will receive injection of ISB 2001 as determined in Part 1.

Trial Locations (11)

2139

RECRUITING

Concord Hospital, Concord

3000

RECRUITING

Peter MacCallum Cancer Center, Melbourne

3065

RECRUITING

St. Vincent's Hospital Melbourne, Fitzroy

4217

RECRUITING

Pindara Private Hospital, Benowa

6009

RECRUITING

Linear Clinical Research, Nedlands

10467

RECRUITING

Montefiore Medical Center, The Bronx

27599

RECRUITING

University of North Carolina, Chapel Hill

53226

RECRUITING

Froedtert Hospital & the Medical College of Wisconsin, Milwaukee

60637

RECRUITING

University of Chicago Medical Center, Chicago

94304

RECRUITING

Standford Cancer Institute, Palo Alto

Unknown

RECRUITING

HCG Hospital, Bangalore

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ichnos Sciences SA

INDUSTRY

NCT05862012 - Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1) | Biotech Hunter | Biotech Hunter